Potential Clinical Uses of Identifying New Hematologic Malignancy Predisposition Gene
2023 ASH
Hamish S. Scott, PhD, and Chris Hahn, PhD, both of Australia’s SA Pathology and Centre for Cancer, discuss ERG, a new predisposition gene for bone marrow failure and hematologic malignancy. Identifying causal germline ERG variants has direct clinical implications for diagnosis, counseling, surveillance, and treatment strategies, according to Drs. Scott and Hahn (Abstract LBA5).
The ASCO Post Staff
Sarah C. Rutherford, MD, of Weill Cornell Medicine, discusses findings of the SWOG S1826 study, which showed nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) improved progression-free and event-free survival and seemed to be better tolerated than brentuximab vedotin plus AVD in patients aged 60 and older with advanced-stage Hodgkin lymphoma (Abstract 181).
The ASCO Post Staff
Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses his findings on risk assessment of CAR T-cell therapy for patients with multiple myeloma. Higher fibrinogen and ferritin values at baseline were associated with inferior overall survival after CAR T-cell therapy, even after controlling for tumor burden. Higher baseline absolute lymphocyte count was also associated with higher risk and grade of immune effector cell–associated neurotoxicity syndrome, an important toxicity to consider for patients receiving CAR T (Abstract 92).
The ASCO Post Staff
Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap in acute myeloid leukemia treatment (Abstract 386).
The ASCO Post Staff
Adam S. Kittai, MD, of The Ohio State University, discusses his data supporting the use of CAR T-cell therapy for patients with Richter’s transformation. Given the high response rate to CD19 CAR T-cell treatment, along with early relapse in most patients, allogeneic stem cell transplantation at response should also be considered, he says (Abstract 108).
The ASCO Post Staff
Mazyar Shadman, MD, MPH, of the University of Washington, discusses new data suggesting that in patients with relapsed large B-cell lymphoma who achieve a complete response, treatment with autologous transplantation may be associated with a lower relapse rate and improved progression-free survival compared with CAR T-cell therapy, including those with early treatment failure (Abstract 781).
